Last reviewed · How we verify
PRA
PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase.
PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase. Used for Invasive candidiasis, Invasive aspergillosis.
At a glance
| Generic name | PRA |
|---|---|
| Sponsor | Scynexis, Inc. |
| Drug class | Echinocandin antifungal |
| Target | β-1,3-glucan synthase (FKS) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Prasifungin is an echinocandin-class antifungal that works by inhibiting β-1,3-glucan synthase, a key enzyme in fungal cell wall biosynthesis. This leads to disruption of the fungal cell wall integrity and fungal cell death. It has broad-spectrum activity against Candida, Aspergillus, and other clinically important fungi.
Approved indications
- Invasive candidiasis
- Invasive aspergillosis
Common side effects
- Elevated liver enzymes
- Infusion-related reactions
- Headache
- Nausea
Key clinical trials
- A Pragmatic Rehabilitation Intervention: The Active Rehab Study (NA)
- Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
- Exercise Reset for Concussion in a Military Environment (NA)
- A Midwife-Led Psychoeducational Intervention to Reduce Pregnancy-Related Anxiety in Low-Risk Pregnant Women (NA)
- Novel Desensitization Kidney Transplantation (PHASE1, PHASE2)
- Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation (PHASE2)
- Blood Salvage From Liver Donors: a Feasibility Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRA CI brief — competitive landscape report
- PRA updates RSS · CI watch RSS
- Scynexis, Inc. portfolio CI